219 related articles for article (PubMed ID: 33231757)
1. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
3. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
5. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
7. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study.
Shirsat PM; Bansal S; Prasad P; Desai RS
J Oral Maxillofac Pathol; 2018; 22(3):353-359. PubMed ID: 30651680
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical and genetic study of BRAF
Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
[TBL] [Abstract][Full Text] [Related]
11. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
12. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
13. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
14. BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis.
Martins-de-Barros AV; da Costa Araújo FA; Faro TF; de Aquino AAT; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; de Oliveira E Silva ED; de Vasconcelos Carvalho M
Head Neck Pathol; 2024 Mar; 18(1):23. PubMed ID: 38504068
[TBL] [Abstract][Full Text] [Related]
15. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
16. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Immunohistochemistry and DNA Sequencing for BRAF V600E Mutation Detection in Mandibular Ameloblastomas.
da Silva Marcelino BMR; Parise GK; do Canto AM; Sassi LM; Sarmento DJS; Costa ALF; Hasséus B; Kjeller G; Schussel JL; Braz-Silva PH
Appl Immunohistochem Mol Morphol; 2021 May-Jun 01; 29(5):390-393. PubMed ID: 33443847
[TBL] [Abstract][Full Text] [Related]
18. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
19. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients.
Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM
J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588
[TBL] [Abstract][Full Text] [Related]
20. Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma.
Kunmongkolwut S; Chaisuparat R
Int J Oral Maxillofac Surg; 2022 Aug; 51(8):1034-1042. PubMed ID: 34998647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]